TherapeuticsMD, Inc.

Period: Jul 6, 2016 to Apr 9, 2017

Lead Plaintiff Deadline: Jun 19, 2017

Summary of Case:


A securities class action has been filed against TherapeuticsMD, Inc. ("TherapeuticsMD") (TXMD) on behalf of all persons who purchased or otherwise acquired TherapeuticsMD common stock between July 7, 2016 through April 9, 2017.  This case has been filed in the USDC - FL Southern.

The Complaint alleges that during the Class Period, Defendants publicly issued materially false and misleading statements and omitted material facts necessary to make Defendants statements not false or misleading concerning the TX-004HR's NDA. As the truth about the TherapeuticsMD's deficient NDA for TX-004HR was revealed, the stock price declined common stock declined $1.50 per share from a closing price of $7.70 per share on April 10, 2017, to close at $6.20 per share on April 10, 2017, a drop of approximately 19.48%.

As a result of the fraudulent conduct alleged herein, Plaintiff and other members of the Class purchased TherapeuticsMD common stock at artificially inflated prices and suffered significant losses and damages once the truth emerged

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.

Join This Action